Meeting
2023 ASCO Annual Meeting
Phase II study of pembrolizumab plus mifepristone in patients with advanced HER2-negative breast cancer.
Authors
Nan Chen
University of Chicago, Chicago, IL
Nan Chen , Elena Michaels , Poornima Saha , Murtuza M. Rampurwala , Olwen Mary Hahn , Frederick Matthew Howard , Gini F. Fleming , Theodore Karrison , Suzanne D. Conzen , Rita Nanda
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Triple-Negative
Clinical Trial Registration Number
NCT03225547
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 1095)
DOI
10.1200/JCO.2023.41.16_suppl.1095
Abstract #
1095
Poster Bd #
316
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
PEMBROBLAD: Real world effectiveness and safety of immune checkpoint inhibitors in patients with advanced urothelial carcinoma with histological variants.
First Author: Karim Amrane Sr.
Poster
2023 ASCO Annual Meeting
Efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient advanced pancreatic adenocarcinoma: An AGEO European Cohort.
First Author: Lorenzo Pilla
Poster
2023 ASCO Genitourinary Cancers Symposium
Safety and efficacy of immune checkpoint inhibitors (ICI) in advanced penile squamous cell carcinoma (PeCa): An international study from the Global Society of Rare Genitourinary Tumors (GSRGT).
First Author: Talal El Zarif
Poster
2021 ASCO Annual Meeting
Phase I/II study to evaluate the efficacy of TAS0313, a cancer peptide vaccine, combined with pembrolizumab for locally advanced or metastatic urothelial carcinoma.
First Author: Ryuji Matsumoto